Supplier News: Dow, Fujifilm, Evotec, Symbiosis & More
The latest from CDMOs, CMOs, and suppliers featuring Kincell Bio, Fujifilm Biotechnologies, Evotec, Symbiosis, Bora Biologics and Ardena.
Appointments
* Dow Names New CEO
* Evotec Appoints New Chief Operating Officer
Biologics Manufacturing
* Kincell Bio Expanding Cell-Therapy Mfg Facility
* Fujifilm Biotechnologies Opens QC Lab in Denmark
* Bora Biologics Completes Engineering & Scale-Up Run
Formulation Development/Drug Product Manufacturing
* Symbiosis Expands QC Lab
* Ardena Opens Bioanalytical Lab
Appointments
Dow Names New CEO
Dow, a global chemicals and material science company, has announced that Jim Fitterling, Chair and Chief Executive Officer (CEO), will become Executive Chair of the Board, effective July 1, 2026. The Dow Board of Directors has appointed Karen S. Carter, currently Chief Operating Officer, as CEO effective July 1, 2026. Carter will also join Dow’s Board of Directors at that time. Richard Davis will continue to serve as Dow’s Independent Lead Director.
Carter has more than three decades of experience at Dow, most recently as Chief Operating Officer, where she has overseen business and operational performance company-wide, with responsibility for Dow’s operating segments and key functional organizations while strengthening customer engagement and accelerating innovation. Previously, Carter served as President of Dow’s Packaging & Specialty Plastics, the company’s largest operating segment. She has also held senior leadership roles across business, commercial, and corporate functions at Dow.
Source: Dow
Evotec Appoints New Chief Operating Officer
Evotec has appointed Dr. Ingrid Müller, Vice President Portfolio Strategy & Execution at CureVac, as Chief Operating Officer (COO). Dr. Müller will be joining Evotec’s Management Board, effective May 1, 2026.
Most recently, Dr. Müller served as Vice President Portfolio Strategy & Execution at CureVac. Prior to that, she held senior international leadership roles at Sanofi and Fresenius Kabi.
Source: Evotec
Biologics Manufacturing
Kincell Bio Expanding Cell Therapy Mfg Facility
Kincell Bio, a CDMO of cell therapies, has announced an investment to expand its Research Triangle Park (RTP), North Carolina, facility.
The RTP facility serves as Kincell Bio’s center of excellence for supply, commercialization, and commercial manufacturing, complementing its early-phase-focused facility in Gainesville, Florida. The RTP site currently houses four ISO 7 cleanroom suites, and the expansion will enable the addition of two more suites, increasing the facility’s capacity to support both autologous and allogeneic cell therapy programs at commercial scale.
The build-out includes the following supporting infrastructure:
- Additional quality control laboratory to support expanded quality control testing;
- MSAT/ASAT laboratory to support later-stage process characterization, process validation, method validation, and technology-transfer activities;
- Microbiology laboratory equipped for sterility testing for product release for both autologous and allogeneic products; and
- Expanded GMP warehouse to increase storage capacity for late-phase clinical development and commercial supply needs.
The expanded facility is projected to be fully operational by the end of the third quarter of 2026.
Source: Kincell Bio
Fujifilm Biotechnologies Opens QC Labo in Denmark
Fujifilm Biotechnologies has opened a new 2,000‑square‑meter quality control (QC) laboratory at its Hillerød, Denmark, commercial‑scale manufacturing site.
The expanded QC footprint will enable bioassay and virology operations. The space supports approximately 100 team members for conducting viral safety testing for drug substance/product release, scaling capacity for cell‑based potency and enzyme-linked immunosorbent assay (ELISA) methods, and conducting raw material and critical total organic carbon cleanability studies. The QC laboratory also incorporates robotics and an ongoing LIMS (laboratory information management system) implementation across the company’s global network of sites.
Source: Fujifilm Biotechnologies
Bora Biologics Completes Engineering & Scale Up Run
Bora Biologics has completed its first 2,000-liter engineering, scale-up, and process confirmation run at its FDA-approved facility in San Diego, California, following the company’s recent $30-million expansion. The engineering run confirms operational readiness of the expanded mammalian manufacturing suites and validates the facility’s upstream, downstream, and quality systems at commercially relevant scale. The campaign also included scale-up of a trastuzumab biosimilar process from 1,000 liters to 2,000 liters.
Source: Bora Biologics
Formulation Development/Drug Product Manufacturing
Symbiosis Expands QC Lab
Symbiosis, a Stirling, UK-based CDMO of injectables, has expanded its quality control (QC) laboratory with the installation of a new 30°C stability chamber. The addition enables Symbiosis to replicate all four ICH‑defined climatic zones to enhance the company’s stability testing capabilities to support global commercial drug-product supply.
Source: Symbiosis
Ardena Opens Bioanalytical Lab
Ardena, a CDMO of drug substances and drug products, and a bioanalytical contract research organization, has opened a new GLP bioanalytical laboratory in Somerset, New Jersey. Arenda had earlier acquired the site in 2025 from Catalent.
The operational bioanalytical laboratory includes controlled sample storage, LC-MS/MS systems, and immunochemistry platforms supporting quantitative analysis for preclinical and clinical studies for small and large molecules. It features 2,500+ square feet of laboratory space, which expands Ardena’s scientific capabilities in North America.
The company plans to further expand the site in the coming months (as reported on April 15, 2026) with a larger bioanalytical laboratory to add additional laboratory space, analytical platforms, including PCR and flow cytometry, and scientific teams to support bioanalysis and biomarker services.
Source: Ardena
